Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768892 | 1.00 | NFE2L2 (0.47) | NFE2L2CES2CES1TRPA1AR | |
| SCHEMBL3662246 | 0.88 | MDM2 (0.40) | NFE2L2CES2CES1TRPA1AR | |
| SCHEMBL3762718 | 0.88 | MDM2 (0.40) | NFE2L2CES2CES1TRPA1AR | |
| SCHEMBL3782296 | 0.88 | NFE2L2 (0.47) | NFE2L2CES2CES1TRPA1 | |
| SCHEMBL3782287 | 0.88 | NFE2L2 (0.47) | NFE2L2CES2CES1TRPA1 | |
| SCHEMBL3778957 | 0.87 | MEN1 (0.38) | NFE2L2CES2CES1ARMDM2 | |
| SCHEMBL3656538 | 0.87 | MEN1 (0.38) | NFE2L2CES2CES1ARMDM2 | |
| SCHEMBL3769663 | 0.85 | NFE2L2 (0.41) | NFE2L2TRPA1NPC1 | |
| SCHEMBL3662353 | 0.85 | NFE2L2 (0.41) | NFE2L2TRPA1NPC1 | |
| SCHEMBL3772509 | 0.81 | NFE2L2 (0.46) | NFE2L2ARNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | NFE2L2 825/4885CES2 295/4885CES1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.